- Home
- JSPR vs ADCT Comparison
JSPR vs ADCT Comparison
Compare JSPR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ADCT
- Stock Information
- Founded
- JSPR 2018
- ADCT 2011
- Country
- JSPR United States
- ADCT Switzerland
- Employees
- JSPR N/A
- ADCT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ADCT Health Care
- Exchange
- JSPR Nasdaq
- ADCT Nasdaq
- Market Cap
- JSPR 85.8M
- ADCT 241.0M
- IPO Year
- JSPR N/A
- ADCT 2020
- Fundamental
- Price
- JSPR $6.70
- ADCT $2.88
- Analyst Decision
- JSPR Strong Buy
- ADCT Strong Buy
- Analyst Count
- JSPR 9
- ADCT 6
- Target Price
- JSPR $59.25
- ADCT $7.80
- AVG Volume (30 Days)
- JSPR 386.0K
- ADCT 915.5K
- Earning Date
- JSPR 08-12-2025
- ADCT 08-05-2025
- Dividend Yield
- JSPR N/A
- ADCT N/A
- EPS Growth
- JSPR N/A
- ADCT N/A
- EPS
- JSPR N/A
- ADCT N/A
- Revenue
- JSPR N/A
- ADCT $75,817,000.00
- Revenue This Year
- JSPR N/A
- ADCT $10.65
- Revenue Next Year
- JSPR N/A
- ADCT $15.05
- P/E Ratio
- JSPR N/A
- ADCT N/A
- Revenue Growth
- JSPR N/A
- ADCT 10.49
- 52 Week Low
- JSPR $3.13
- ADCT $1.05
- 52 Week High
- JSPR $26.05
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- JSPR 71.26
- ADCT 51.19
- Support Level
- JSPR $5.35
- ADCT $2.55
- Resistance Level
- JSPR $5.72
- ADCT $2.88
- Average True Range (ATR)
- JSPR 0.53
- ADCT 0.25
- MACD
- JSPR 0.11
- ADCT -0.09
- Stochastic Oscillator
- JSPR 82.72
- ADCT 21.13
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).